Dynavax(US:DVAX) Prnewswireยท2025-11-05 21:01Core Insights - Dynavax Technologies Corporation reported significant progress in its strategic initiatives during Q3 2025, particularly in the commercial performance of HEPLISAV-B and advancements in its vaccine pipeline [2][5][6]. Business Updates - Dynavax entered into an exclusive license agreement with Vaxart for its oral COVID-19 vaccine candidate, which is currently in Phase 2b clinical trials [3][6]. - The company authorized a new share repurchase program of up to $100 million, reflecting confidence in its future and commitment to returning value to shareholders [4][7]. Financial Highlights - HEPLISAV-B achieved quarterly net product revenue of $90 million, marking a 13% year-over-year increase from $79.3 million in Q3 2024 [5][16]. - Total revenues for Q3 2025 were $94.9 million, an 18% increase compared to $80.6 million in Q3 2024 [16]. - GAAP net income for Q3 2025 was $26.9 million, or $0.23 per share, compared to $17.6 million, or $0.13 per share, in Q3 2024 [16][31]. Market Position - HEPLISAV-B's total estimated market share in the U.S. increased to approximately 46%, up from 44% in Q3 2024, with retail market share growing to about 63% from 55% [10][16]. - The U.S. hepatitis B adult vaccine market is expected to peak at over $900 million in annual sales by 2030, with HEPLISAV-B projected to achieve at least 60% market share [10][16]. Clinical Pipeline - Dynavax is advancing its shingles vaccine candidate Z-1018, which has shown positive topline data in clinical trials, and is expected to report further results in 2026 [11][12]. - The company is also developing a plague vaccine candidate and a Lyme disease vaccine candidate, both leveraging its CpG 1018 adjuvant technology [9][12][16].